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Effect of thromboxane inhibition on tubuloglomerular feedback in
hydronephrotic kidneys. The tubuloglomerular feedback (TGF) system
is less sensitive after extracellular volume expansion (yE). In rats with
partial ureteral obstruction, however, we have previously found in-
creased TGF sensitivity during such expansion. Thromboxane A2
(TXA2) has been reported to be increased in the hydronephrotic kidney,
and the present study was undertaken to investigate whether TXA2
might be responsible for these findings. The TGF characteristics were
studied, by means of the stop-flow technique, in control and hydrone-
phrotic rats before and after intravenous injection of either a throm-
boxane synthetase inhibitor or a thromboxane receptor antagonist
during hydropenia. After yE, TGF was studied again. Proximal tubular
stop-flow pressure (Pd) was measured during perfusion of the loop of
Henle with a modified Ringer's solution, the maximal response (P,,f) to
an increased tubular flow rate was determined and the tubular perfusion
rate which elicited a half-maximal decrease in designated the
turning point, was recorded. In hydropenic control or hydronephrotic
animals, TXA2 did not permanently change the TGF characteristics.
During VE of the TXA2-blocked hydronephrotic animals, blocked both
with synthetase inhibitor or receptor-antagonist, TGF was reset to a
lower sensitivity like VE controls, as indicated by a high turning point
and a low APf. It was therefore concluded that thromboxane A2
inhibition does not influence the TGF system in hydropenia, but that the
production of thromboxane A2 is responsible for the resetting of the
TGF system during VE in hydronephrotic animals.
In several studies on the TGF system after extracellular
volume expansion, a decrease in the sensitivity of this mecha-
nism has been observed [1—3]. In contrast, in a previous study
on partial unilateral ureteral occlusion it was found that the
sensitivity and activity of the TGF control system was in-
creased during volume expansion [4]. It has also been reported
that the production of TXA2, which is a potent vasoconstrictor,
is increased in the kidney in different pathophysiological con-
ditions, including complete ureteral obstruction [5—7]. Further-
more, hemodynamic improvements have been noted after inhi-
bition of thromboxane synthetase in kidneys subjected to
ureteral occlusion [8—101.
The present study was performed to investigate the effect of
blocking the synthesis of arachidonic acid metabolites, with
special reference to TXA2, on the resetting of the TGF mech-
anism in animals with chronic unilateral partial ureteral occlu-
sion. The rats were treated either with a thromboxane syn-
thetase inhibitor (TXSI; UK-38.485, Pfizer Laboratories, New
York, New York, USA), a thromboxane/prostaglandin endo-
peroxide receptor antagonist (TXRA; L-670.596, Merck-Frosst)
or with indomethacin (INDO). The results were compared with
those from sham-operated animals treated with the same sub-
stances. The effects of volume expansion in hydronephrotic rats
treated with these drugs were compared with those in untreated
hydronephrotic rats.
Methods
Partial ureteral obstruction
Partial ureteral obstruction was produced in 23 weanling
Sprague-Dawley rats, 3 weeks old, by a method described
previously [4, 11]. In short, the rats were anesthetized by an
intraperitoneal injection of methohexital (Brietal, Eli Lilly &
Co., Indianapolis, Indiana, USA; 30 mg*kg body wt). The
abdomen was opened by a midline incision. The left ureter was
dissected free and buried in the underlying psoas muscle. The
muscle edges were then fitted together with sutures, and the
abdomen was closed with Ethilon. In this way the ureter was
submitted to constant pressure. After the operation, when the
rats were fully awake, they were returned to their cage. In
sham-operated animals the same operational procedure as
mentioned above was undertaken, except that the ureter was
not placed in the psoas muscle. The animals were allowed free
access to food (Ewos, Södertälje, Sweden) and tap water up to
the time of the experiment, which was performed three to six
weeks later. Hydronephrosis was graded according to the
pelvic volume, which was determined after the completion of
the experiments. The ureter was ligated and cut. The kidney
was removed by blunt dissection, weighed and then sliced,
whereby the renal pelvis was completely emptied. The kidney
was then weighed again and the pelvic volume was calculated
by subtraction. All experiments were performed on kidneys
with a mean pelvic volume of 0.90 0.15 ml*g kidney wet
wt, compared with a mean pelvic volume in control animals of
0.18 0.02 ml*g.
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General preparation
The animals were anesthetized by an intraperitoneal injection
of thiobutobarbital sodium (mactin, Byk-Gulden, Constance,
FRG, 120 mg*kg body wt) and placed on a temperature-
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regulated heating pad, in order to keep the body temperature at
37.5°C. They were tracheotomized and catheters were placed in
the femoral vein and artery. Maintenance fluid (0.9% NaC1, 5.0
ml*kg body wt an hr) was infused into the femoral vein. The
mean arterial pressure (Pa) was measured continuously through
the catheter in the femoral artery. The ureters were cannulated
close to the bladder through an abdominal midline incision. The
left kidney was exposed through a left subcostal flank incision,
dissected free and placed in a lucite cup. The cup was lined and
the kidney loosely surrounded with saline-soaked cotton. Care
was taken to avoid compression of the vascular pedicle. The
kidney was then fixed with a 3% agar-agar solution and its
surface was covered with mineral oil to prevent it from drying.
Micropuncture
For characterization of the TGF, a system for micropuncture
of the tubules on the kidney surface was used. Randomly
chosen proximal tubules were identified by injecting small
amounts of stained fluid (lissamine green in I M NaCI) with a
glass pipette (tip outer diameter [OD] 2 to 3 m) connected to a
servo-nulling micropressure device (WP Instruments, New
Haven, Connecticut, USA) and the tubular free-flow pressure
(Pt) was recorded. With a second pipette (OD 7 to 9 JLm) a solid
wax block was placed in an early segment of the proximal
tubule [121. The tubular fluid pressure proximal to the block,
'sf, which both theoretically and in practice is a good estimate
of the glomerular capillary pressure [13—17], could then be
measured. A third micropipette connected to a microperfusion
pump (Hampel, Frankfurt, FRG) was positioned in the last
accessible segment of the proximal tubule. The composition of
the perfusion solution was: 140 mrt NaCI, 4 m NaHCO3, 5 mM
KCI, 2 mM CaCI2, 1 mrvt MgCI2, 7 m'vi urea, and 2 g*liter
lissamine green, pH 7.4 TGF sensitivity was measured as
changes in sf while the loop of Henle was being perfused at
different rates. The maximal sf response that could be released
with flow, was determined. The perfusion rate was
randomly varied from 0 to 40 and 40 toO nl*minl in steps of 2.5
to 5 nl*minJ and the rate that elicited half-maximal sf'
designated the turning point (TP), was recorded. All pressures
were recorded on a Servogor 460 recorder (BBC, Metrawatt
GMBH, Wien, Austria).
Experimental protocol
TGF was characterized after a 30-minute stabilization period
and again after i.v, injection of the following drugs:
Thromboxane synthetase inhibitor UK-38.485 (Pfizer, Sand-
wich, Kent, UK) was injected in a dose of 20 mg*kg body wt
in eight hydronephrotic and eight sham-operated animals
(TXSI).
Indomethacin (Confortid, Dumex, Copenhagen, Denmark)
was injected in a dose of 2 mg*kg body wt in six hydrone-
phrotic and five sham-operated animals (INDO). Thromboxane/
prostaglandin endoperoxide receptor antagonist L-670.596
(Merck-Frosst, Canada) was injected in a dose of 2 mg*kg
body wt in five hydronephrotic rats (TXRA).
Volume expansion (5% of body wt*hr with 0.9% NaCl) was
started 60 to 70 minutes after drug injection and the final
measurements were commenced within 30 minutes after the
start of the volume expansion.
The experiments were performed in two different laboratories
and at different time periods. In the first series of experiments
results were obtained from sham-operated control rats (series I)
and compared with hydronephrotic rats where the effect of
TXSI and INDO were studied (series II).
In the second series of experiments, where the TGF mecha-
nism was measured before and during VE (series III), control
animals were compared with hydronephrotic animals using
TXRA treatment before and after VE (series IV).
Statistics
The material was tested by one-way analysis of variance. To
allow more than one comparison with the same variable, the
Bonferroni method was used; this states a significance level of
P/M, where Mis the number of comparisons to be made [18]. P
< 0.05/M was accepted for significance. Values are given as
mean SE; N refers to the number of observations (nephrons).
Table 1. Tubular pressures in sham-operated rats, series I
1a Pf M' ip
nl*min_J rn/nmm Hg
Sham-operated
Sham-operated + TXSI
Sham-operated + INDO
118
109
113
2
2
4
13.5
13.1
13.6
0.2
0.6
0.6
39.2 1.0
42.4 1.3
36.9 0.8°
9.3 0.9
6.6 0.9
8.9 0.7
19.7 0.5
18.2 0.9
26.1 l.0"
13/25
8/11
5/8
Values are given as mean SE. Abbreviations are: a' mean arterial pressure; P, tubular free-flow pressure; PS, tubular stop-flow pressure; TP,
turning point; rn/n, animals/nephrons; TXSI, thromboxane synthetase inhibition; INDO, indomethacin.
a P < 0.05 compared with TXSIb P < 0.05 compared with sham-operated
40
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0
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Fig. 1. The estimated variation in turning point (ni/mm) with time after
injection of thromboxane synthetase inhibitor in sham-operated ani-
mals. Dotted line indicates pre-injection values. Arrow on x axis
indicates injection of inhibitor.
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Table 2. Tubular pressures in rats with partial ureteral obstruction from series II
Pa I', P1 Pf TP
nl*min rn/nmm Hg
Hydronephrosis
Hydronephrosis +
Hydronephrosis +
Hydronephrosis +
Hydronephrosis +
TXSI
INDO
TXSI + VE
INDO +VE
124 2
125 3
118 4
133 4
117 4
12.7 0.3
15.9 08a,b
12.5 0.4
17.2 0.7a
17.0 l.5aI
38.5 0.8
43•7 1,7a.b
36.4 1.4
44.0 l.7
43•4 1,2a.b
9.4 0.8
9.4 1.0
11.2 1.1
5.5 l.0C
6.0
21.2 0.9
24.1 1.3
27.3 l.2a33.3 O.9
30.1 0.8a
14/21
8/10
6/10
8/10
6/8
Values are given as mean SE. Abbreviations are: a' mean arterial pressure; P1, tubular free-flow pressure; Pf, tubular stop-flow pressure; TP,
turning point; rn/n, anjmals/nephrons; TXSI, thromboxane synthetase inhibition; INDO, indomethacin; yE, volume expansion.
a p < 0.05 compared with untreated rats
b P < 0.05 compared with INDO, hydropenic
P < 0.05 compared with TXSI, hydropenic
E
C
0
C
C
I-
C Hydronephrosis
+ INDO
Results
Series I
The results from the first series of experiments with sham-
operated control are shown in Table 1. Here it can be seen that
the addition of TXSI to hydropenic animals did not change any
of the recorded parameters. In contrast, the addition of INDO
significantly lowered P compared with the animals given
TXSI, while TP in INDO group was increased significantly
compared with both control and TXSI treated animals. In
Figure 1 are shown the TP and its variation with time, after the
injection of TXSI in sham-operated control animals, It can be
seen that initially after TXSI injection, the TP was high, but
within 30 to 40 minutes returned to the normal preinjection
value, 18.2 nl*min compared with a control value of 19.7
nl*min . We have in this study only used values taken in
between 40 minutes and 2.5 hours after the injection of TXSI.
Series II
The results from the second series of experiments with
hydronephrotic animals treated with TXSI or INDO and then
volume expanded are given in Table 2 and Figure 2. From a
previous study [4J we found, as can be seen in Figure 2A, that
VE of hydronephrotic kidneys significantly increased feedback
sensitivity with a reduction in TP from 23.6 to 14.4 nl*min. In
Table 2 and Figure 2 it can be seen that both TXSI and INDO
treatment during VE raised TP in a normal way to 33.3
nl*min and 30.1 nl*min I, respectively. In this situation it
was also found that LPS was reduced to 5.5 and 6.0 mm Hg,
respectively, compared with the control value of 9.4 mm Hg.
When INDO was given, part of the shift in TP already took
place when the substance was given. It can also be noted that
both P- and P, was already increased at TXSI treatment.
Series Ill
In Table 3 the tubular pressures in control animals during
hydropenia and VE are shown. In this control group belonging
to a second set of experiments it is shown that volume expan-
sion rose TP from 18.3 to 32.1 nl*min and reduced PSf from
8.6 to 3.6 mm Hg, and increased from 37.1 to 46.6 mm Hg.
Series IV
The results from the hydronephrotic animals in the second set
of experiments, using the TXRA treatment, are shown in Table
4 and Figure 3. There it can be seen that YE of hydronephrotic
4040
30
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30
A Hydronephrosis B Hydronephrosis
+ TXSI
40
30
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I I I I
Hydropenia Volume Hydropenia Volume
expansion expansion
20
10
Hydropenia Volume
expansion
Fig. 2. Mean turning point (nl*min) in each
individual animal in untreated, hydronephrotic
kidneys, and in rats treated with thromboxane
synthetase inhibitor (TXSI) or indomethacin
(INDO), during hydropenia and during
volume expansion. Values from the same
animals are connected with lines. The animals
in the left hand panel are from a previous
study [4].
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Table 3. Tubular pressures in control rats from series III
Pa P Pf TP
nl*min rn/nmm Hg
Hydropenia 128 3 11.4 0.5 37.1 1.0 8.6 1.2 18.3 0,9 4/8
Volume expansion 126 2 15.2 Ø7 46.6 2.5a 3.6 0.6a 32.1 l.6 4/9
Values are given as mean SE. Abbreviations are: a' mean arterial pressure; P' tubular free-flow pressure; Ps,., tubular stop-flow pressure; TP,
turning point; rn/n, anirnals/nephrons.
P < 0.05 compared with hydropenia
Table 4. Tubular pressures in rats with partial ureteral obstruction from series IV
1a Pt Pa Paf TP
nl*minl rn/nmm Hg
Hydronephrosis 121 2 11.8 0.3 34.6 0.9 10.7 0.9 17.9 0.5 9/20
Hydronephrosis + TXRA 126 1 12.7 0.3 35.6 2.4 9.1 1.4 19.1 1.3 5/7
Hydronephrosis + VE 112 I 13.6 0.4a 37.1 1.4 8.6 0.8 15.3 0,6a 4/13
Hydronephrosis ÷ TXRA + YE 121 IC 16.6 04b.c 40.9 1,6b 6.5 0.6 28.6 1,3t,, 5/15
Values are given as mean SE. Abbreviations are: a' mean arterial pressure; P1, tubular free-flow pressure; tubular stop-flow pressure; TP,
turning point; rn/n, animals/nephrons; TXRA, thromboxane receptor blockade; YE, volume expansion,
a P < 0.05 compared with untreated rats, hydropenia
b P < 0.05 compared with TXRA
P < 0.05 compared with untreated rats, volume expansion
C Hydronephrosis
+ TXRA
Fig. 3. Mean turning point (nl*mi,f) in each
individual animal in control animals,
untreated /zydronephrotic rats and in
hydronephrotic rats treated with
thromboxane/prostaglandin endoperoxide
antagonist (TXRA), during hydropenia and
during volume expansion. Values from the
same animals are connected with lines.
animals, like in a previous study [41 and mentioned above,
increased TGF sensitivity by a reduction in TP; in this series the
reduction was from 17.9 to 15.3 nl*minl. In this series of
experiments the addition of TXRA normalized the response of
the hydronephrotic kidneys to VE as in the series of TXSI
treatment, with a shift in TP from 19.1 to 28.6 nl*min. It is
also interesting to note that in these animals the also
increased to 40.9 from 35.6 mm Hg, and that iPsf was reduced
from 9.1 to 6.5 mm Hg. The shift in TP from series III and IV
can be seen in Figure 3.
Discussion
In this study the effets of inhibition of arachidonic acid
metabolite synthesis on glomerular dynamics were studied in
control, sham-operated and hydronephrotic animals. The influ-
ence of thromboxane on TGF in control rats have been inves-
tigated previously, but with conflicting results. Welch and
Wilcox [l9J reported reduced TGF sensitivity after thrombox-
ane synthetase inhibition, while Franco, Bell and Navar [201
found no effect at all on glomerular dynamics after treatment
with the same drug. In the present study there was an initial
increase in TP which gradually returned to control values. The
discrepancies between the above-mentioned results might be
due either to the fact that the measurements were performed at
different times after the inhibition, or to the difference in the
dose of the inhibitor. Welch and Wilcox used a very high dose
of TXSI, and it is known that such very high doses also inhibit
cyclooxygenase [101, an effect which has been shown to reduce
A Control B Hydronephrosis
40
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C
C
I—
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Hydro'penia Vol'urne Hydro'penia Vo1.ime Hydropenia Volume
expansion expansion expansion
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TGF sensitivity. The recommended dose of 20 mg*kg body
wt has been shown to significantly reduce measured TXB2
levels (the stable metabolite of TXA2), to 17% of the control
value, 4.5 hr after i.v. injection (Dr. M. Randall, Pfizer Labo-
ratory, unpublished observations). Administered intraperitone-
ally, TXB2 production measured from glomeruli was decreased
to undetectable values, even after eight hours from the admin-
istration [7]. In a recent publication, Jackson et a! showed that
urinary excretion of TXB2, which is supposed to reflect throm-
boxane production from the kidney, was suppressed by approx-
imately 80%, 2.5 hours after i.v. injection of I mg*kg body wt
[21]. All measurements in this study were made within 2.5 hours
after drug injection.
In the present study, only values obtained 40 minutes or more
after injection were included, since TP reaches a steady state at
that time. In the hydronephrotic kidneys, the TGF response
was also determined during this time period.
Several investigators have found increased thromboxane
levels in the kidney under pathophysiological conditions, in-
cluding ureteral obstruction [5—7]. Even though TXA2 produc-
tion was not measured in this study, the results from interfering
with both TXA2 formation and receptor blockade, at least
indirectly, indicate that TXA2 formation was of importance for
the pathophysiology in this experimental model. An increased
arachidonic acid metabolism is mostly located in the renal
cortex [22, 23], and at least to some extent in the glomerulus
[24, 25]. The cellular sites of enhanced thromboxane synthesis
during hydronephrosis seem to be in invasive inflammatory
cells and proliferated fibroblasts as seen in the damaged cortex
[26, 27].
One possible role of TXA2 could be to serve as a regulator of
preglomerular vasoactivity, with consequent regulation of the
glomerular filtration rate (GFR) in situations of impaired renal
function. In a previous study, Yarger, Schocken and Harris [8]
found that the reduction in blood flow and GFR following
ureteral obstruction was antagonized by TXA2 inhibitors, an
effect that was not observed after INDO treatment. In the
present study there was a discrepancy of the results obtained
from TXSI and TXRA treated animals in the hydropenic
hydronephrotic situation. TXSI caused the tubular pressures to
increase, while TXRA had no such effect. This difference in
response could possibly be explained by shunting of endoper-
oxides to prostacyclin, which maybe would increase tubular
pressures after TX synthetase inhibition. Such shunting has
been reported from previous studies with other thromboxane
synthetase inhibitors, while others did not find any increases of
prostacyclin concentration in response to blockade of the
thromboxane pathway [28—30]. Cook et a! reported increased
serum levels of prostacyclin, while glomerular production was
unaltered in response to TXSI [7]. INDO had no effect on the
tubular pressures. Since INDO blocks both the formation of
thromboxane synthetase and prostaglandins, this could indicate
a release of both vasodilatory prostaglandins and vasoconstric-
tory thromboxanes in the animal with ureteral obstruction,
under hydropenic conditions.
Another conceivable function of TXA2 in partially occluded
kidneys might be to control resetting of the TGF sensitivity to
prevent kidney damage. In the acute phase of complete ureteral
obstruction there is an increase in pelvic pressure that can
almost reach glomerular capillary pressure minus the plasma
oncotic pressure [31]. With sustained obstruction the pelvic
pressure decreases and in the chronic partially obstructed
kidney an almost normal pressure is found (P. Morsing &
A.E.G. Persson, unpublished observations). This initial in-
crease in pressure could be one factor causing renal parenchy-
mal damage: It is then possible that, in the hydropenic hydro-
nephrotic kidney, the renal function will have adapted to a
lower urine flow because of its restricted ability to excrete
urine. During volume expansion of the hydronephrotic animal,
the increased sensitivity of TGF would keep GFR and the urine
formation at a low level, which could prevent the pelvic
pressure rise and eventually prevent further damage to the renal
parenchyma. Supportive of this theory is that an increased
pelvic pressure was found during YE in hydronephrotic kidneys
when thromboxane synthetase was blocked [32].
In previous reports it has been proposed that resetting of the
TGF is mediated through changes in net interstitial pressure
(Pnet) [3]. Even though 'net increased during volume expansion
in the hydronephrotic kidney, TGF became reset toward high
sensitivity and activity [4]. This implies that other factors
besides flet are important for the resetting of TGF, and earlier
studies have shown that an intact prostaglandin system is
necessary for TGF to function properly [33, 34]. The most
striking evidence for TXA2 involvement in the resetting of TGF
in hydronephrosis was the fact that both after TXSI and TXRA
injection, volume expansion caused a completely different
response to alteration of loop of Henle perfusion. The high TP
observed were the same as the TP found, during yE, in control
rats and are in line with that normally seen after volume
expansion [2, 3]. This is also what would have been expected
from the high net in this situation [3].
In conclusion, we propose: that thromboxane A2 is of no
importance to the TGF in the normal kidney; that thromboxane
A2 is responsible for the increased sensitivity of the TGF
control mechanism observed after volume expansion, in
chronic partial ureteral obstruction; and that this thromboxane
A2 production may have a protective function in the pathophys-
iology of hydronephrosis.
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